Colon cancer survivors: medications and risk of recurrence

Non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal therapy (HT) have been shown to decrease incident colon cancer. Little is known of their effect on persons with a history of colon cancer and presumably at high risk for the development of another malignant lesion—an expanding population of individuals as survival with this disease has been significantly improving over the last twenty years. The objective of the "Colon Cancer Survivors: Medications & Risk of Recurrence" study led by Dr. Christine Johnson (HFHS) is to determine whether NSAIDs or HT are associated with recurrence or survival among individuals with a previous diagnosis of colorectal cancer. A cohort of over 1300 subjects is being followed for at least five years using medical record review, for new evidence of disease, recurrence and survival outcome. Using automated pharmacy data, the timing of use and exposure to NSAIDs and HT will be analyzed among these cancer survivors. Investigators from CRN sites Henry Ford and HealthPartners are collaborating on this study, which was funded as an R01 in Spring 2000. The study provided data for an investigation of racial and age differences in post-treatment surveillance of patients with colorectal cancer.

<< Back to the list of CRN projects

Loading…